Manufacturing & Packaging

Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions

Latest construction plan continues CDMO’s vision for biopharma expansion

CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand

After previously going bankrupt, center is now under US ownership for the first time

Swiss organization will take patient-centric approach towards developing injectables

Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal

Irvine, CA, location will house 40,000 square feet of oral solid dosage forms

Swiss CDMO’s expansion at recently opened Guangzhou plant expected to be ready by next year

Venture anticipated to more than double single-use bioreactor mammalian cell-culture capacity on site

CDMO's expansion of Rensselaer, NY, facility will help grow its API division

Acquisition addresses the need for meeting healthcare sector’s patient support demand

Cardiff center will help produce lipids that are necessary for mRNA Covid vaccines

Developments include the creation of a new microbial facility, expansion of mammalian center

Deal allows for bicoastal expansion of pharmaceutical services

End result is an enhanced method for developing vaccinia capping enzyme (VCE), parties say

Manufacturing center expected to integrate data analytics, machine learning into production process

Sets the scene for a messenger RNA production facility in Canada

Michigan site adds 110,000 square feet to its production footprint as company aims to meet additional demand

Acquisition boosts C&GT portfolio by 622,000 square feet, as CDMO eyes global expansion

CDMO's North Carolina development adds over 3,700 square feet worth of manufacturing space, equipment

Among focal points, New Jersey location will support clinical research, pharmacovigilance

CDMO says BFS capacity can now reach over 2 billion units yearly

State and regional economic-development authorities compete fiercely for siting new pharma enterprises, and holding onto the ones they have. But pharma’s stupendous growth in investment is giving all regions a boost

Acquisition of US partner establishes Sanofi's plan to advance messenger RNA technology for vaccines, therapeutics

Baltimore facility production was stopped after FDA flagged millions of contaminated doses